tbuckley/cabot-search huggingface dataset:
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Authors: Kathryn E. Stephenson, Boris Julg, C. Sabrina Tan, Rebecca Zash, Stephen R. Walsh, Charlotte-Paige Rolle, Ana N. Monczor, Sofia Lupo, Huub C. Gelderblom, Jessica L. Ansel, Diane G. Kanjilal, Lori F. Maxfield, Joseph Nkolola, Erica N. Borducchi, Peter Abbink, Jinyan Liu, Lauren Peter, Abishek Chandrashekar, Ramya Nityanandam, Zijin Lin, Alessandra Setaro, Joseph Sapiente, Zhilin Chen, Lisa Sunner, Tyler Cassidy, Chelsey Bennett, Alicia Sato, Bryan Mayer, Alan S. Perelson, Allan deCamp, Frances H. Priddy, Kshitij Wagh, Elena E. Giorgi, Nicole L. Yates, Roberto C. Arduino, Edwin DeJesus, Georgia D. Tomaras, Michael S. Seaman, Bette Korber, Dan H. Barouch
Journal: Nature Medicine (2021)

Abstract Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg –1 in HIV-uninfected adults and HIV-infected adults on antiretroviral therapy (ART), as well as a multicenter, open-label trial of one infusion of PGT121 at 30 mg kg –1 in viremic HIV-infected adults not on ART (no. NCT02960581). The primary endpoints were safety and tolerability, pharmacokinetics (PK) and antiviral activity in viremic HIV-infected adults not on ART. The secondary endpoints were changes in anti-PGT121 antibody titers and CD4 + T-cell count, and development of HIV-1 sequence variations associated with PGT121 resistance. Among 48 participants enrolled, no treatment-related serious adverse events, potential immune-mediated diseases or Grade 3 or higher adverse events were reported. The most common reactions among PGT121 recipients were intravenous/injection site tenderness, pain and headache. Absolute and relative CD4 + T-cell counts did not change following PGT121 infusion in HIV-infected participants. Neutralizing anti-drug antibodies were not elicited. PGT121 reduced plasma HIV RNA levels by a median of 1.77 log in viremic participants, with a viral load nadir at a median of 8.5 days. Two individuals with low baseline viral loads experienced ART-free viral suppression for ≥168 days following antibody infusion, and rebound viruses in these individuals demonstrated full or partial PGT121 sensitivity. The trial met the prespecified endpoints. These data suggest that further investigation of the potential of antibody-based therapeutic strategies for long-term suppression of HIV is warranted, including in individuals off ART and with low viral load.
1140P Validation of a deep learning model for the classification of lung cancer in a large cohort of biopsied samples
Authors: G. Toyokawa, Y. Yamada, N. Haratake, Y. Shiraishi, T. Takenaka, T. Tagawa, M. Shimokawa, K. Yamazaki, S. Momosaki, S. Takeo, I. Okamoto, Y. Oda
Journal: Annals of Oncology (2021)
Healthcare workers must be given priority access to fuel, say unions
Authors: Abi Rimmer
Journal: BMJ (2021)

Unions including the BMA have called on the government to give health and care workers priority access to fuel.

It has been reported that the Petrol Retailers Association (PRA), which represents nearly 5500 of the UK’s 8000 filling stations, said on 26 September that up to two thirds of petrol stations had run out of fuel, with the rest “partly dry and running out soon.”1

In light of the shortage, unions have been calling for health and care staff to be given priority access to fuel to ensure they …
1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients
Authors: B. Obispo, R. Hernandez, P. Cruz, A. Fernandez Montes, M. Gil Raga, O.A. Garcia, J. Rogado, E. Asensio-Martinez, N. Piera Molons, V. Pacheco-Barcia, M.H. López de Ceballos, J.M. Cano, L. Ostios Garcia, M. Antoñanzas Basa, D. Lorente, A. Manzano Fernández, S. Hernando Polo, M. Gonzalez Moya, T. Garcia, C. Calderon
Journal: Annals of Oncology (2021)
1143P Virtual amplicons for methylation-sensitive restriction enzyme quantitative PCR (MSRE-qPCR) derived from genome-wide DNA methylation sequencing: Application to prediction of breast cancer neoadjuvant chemotherapy response
Authors: A.I. Kalinkin, V. Sigin, E. Ignatova, A.S. Tanas, V.V. Strelnikov
Journal: Annals of Oncology (2021)
442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
Authors: M. Español-Rego, C. Fernández-Martos, M.E. Elez Fernandez, C. Foguet, L. Pedrosa, N. Rodríguez, A. Ruiz, E. Pineda, J. Cid, R. Cabezón, H. Oliveres, M. Lozano, A. Ginés, A. Garcia-Criado, M. Cuatrecasas, F. Torres, M. Cascante, D. Benítez-Ribas, J. Maurel
Journal: Annals of Oncology (2021)
70P A DNA methylation markers panel for prediction of luminal B breast cancer neoadjuvant chemotherapy response by quantitative PCR
Authors: A. Nikolaeva, V. Sigin, A.I. Kalinkin, N.V. Litviakov, E. Slonimskaya, M. Tsyganov, A. Kharitonova, I. Vinogradov, M. Vinogradov, V.V. Strelnikov, A.S. Tanas, I. Vinogradov
Journal: Annals of Oncology (2021)
384O Laparoscopic versus open hemihepatectomy: The ORANGE II PLUS multicenter randomized controlled trial
Authors: R.S. Fichtinger, L. Aldrighetti, R. Troisi, M. Abu Hilal, R. Sutcliffe, M. Besselink, S. Aroori, K. Menon, B. Edwin, M. D'Hondt, V. Lucidi, F. Ulmer, R. Díaz-Nieto, F. Ratti, C. Kümmerli, L. Brandts, S. Pugh, Z. Eminton, J. Primrose, R. van Dam
Journal: Annals of Oncology (2021)
Abstract 19902: Differences in Targeted Temperature Management Utilization by Gender
Authors: Sarah M Perman, David F Gaieski, Stacie L Daugherty, Edward P Havranek, Benjamin S Abella, Michael W Donnino, Anne V Grossestreuer
Journal: Circulation (2016)

Introduction: Gender differences have been observed in various disease states in acute emergency care, for example women receive less or delayed emergent angiography for myocardial infarction and l...
Endoscopic management of postesophagectomy leak with modified clip-and-loop technique
Authors: Sridhar Sundaram, Raosaheb Rathod, Utkarsh Chhanchure, Prachi Patil, Kiran Mane, Devayani Niyogi, Shaesta Mehta
Journal: Endoscopy (2021)

A 75-year-old woman with carcinoma of the lower esophagus underwent esophagectomy with proximal gastrectomy. On the 6th day after surgery, she developed breathlessness with chest pain and high-grade fever. Computed tomography (CT) of the chest showed a leak from the anastomotic site tracking into the right pleura ([Fig. 1]). Upper gastrointestinal endoscopy showed dehiscence of approximately 1 cm at the anastomotic site ([Fig. 2]). After multidisciplinary discussion, endoscopic rent closure was planned. The edges of the defect were ablated using argon plasma coagulation. Due to angulation, complete apposition of the defect using clips was not feasible. Resolution clips (Boston Scientific, Marlborough, Massachusetts, USA) were applied to the edges of the defect. An endoloop (Olympus Medical, Tokyo, Japan) was applied to tie the clips together to close the defect completely ([Video 1]) ([Fig. 3]). There was a decrease in the right pleural drain output, with contrast swallow showing no leak on day 5 ([Fig. 4]). Repeat endoscopy on day 14 showed a completely healed defect at the anastomotic site ([Fig. 5]).
Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries
Authors: Clémence Martin, Pierre-Régis Burgel
Journal: European Respiratory Journal (2021)

Cystic fibrosis (CF), an autosomal recessive disease related to mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, is the most prevalent severe genetic disease in Caucasian populations [1]. Although the disease affects multiple organs, respiratory disease is the major manifestation of CF and is often responsible for premature death [2], which often occurred in the first years of life before the implementation of modern CF care [3]. Over the past decades, progress in therapeutic management has resulted in a dramatic improvement in the prognosis of people with CF [4]. In a study published more than 20 years ago, Fogarty et al . [5] compared median age at death in seven countries (USA, and Australasian and European countries) and reported that median age at death improved from 8 years in 1974 to 21 years in 1994, albeit with marked differences between countries. More recent studies have confirmed improvement in median age of survival, which was 40.6 years in US patients and 50.9 years in Canadian patients, in a study that used data from between 2009 and 2013 [6]. In European countries, contemporary studies have reported increases in the number of adults with CF [7, 8], with a better prognosis in countries belonging to the European Union (EU) than in those outside of the EU [7, 8], mostly located in Eastern Europe, in which access to appropriate CF care is less available [9]. Collectively these data suggest that prognosis improvement in patients with CF is heavily dependent on the quality of the CF healthcare system. Survival is improving for people with cystic fibrosis in European countries albeit with persistent disparities in prognosis among countries <https://bit.ly/34GF3SA>
463P Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC): Early efficacy results from GI-SCREEN CRC Ukit study
Authors: S. Yuki, H. Taniguchi, T. Masuishi, M. Shiozawa, H. Bando, K. Yamazaki, T. Nishina, H. Yasui, T. Denda, Y. Sunakawa, H. Satake, K. Yoshida, A. Kanazawa, E. Oki, Y. Okugawa, H. Ebi, Y. Abe, S. Nomura, C. Asano, T. Yoshino
Journal: Annals of Oncology (2021)
1301P Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
Authors: A.M. VanderWalde, J. Lee, K. Tolba, A. Ward, M. Cooper, R.S.P. Huang, J. Venstrom, G. Oxnard, A.B. Schrock, L. Schwartzberg
Journal: Annals of Oncology (2021)
Papers of Wade Hampton Frost, M.D.: A Contribution to Epidemiological Method
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
743P Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
Authors: R. Shotton, X. Ren, M. Randhawa, M. Tilby, I. Vazquez, S. Williams, R.M. Glasspool, C. Gourley, A.R. Clamp, C.L. Mitchell, G.C. Jayson, J. Hasan
Journal: Annals of Oncology (2021)
169P Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study
Authors: X. Chen, S. Zhang, X. Li, Y. Zhang, Y. Li, H. Kang, H. Guan, Q. She, X.B. Ma, Y. Diao, D. Liu, W. Min, M. Liu, F. Wu, C. Feng
Journal: Annals of Oncology (2021)
1671MO Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Authors: L. Eng, R. Sutradhar, Y. Niu, N. Liu, Y. Liu, Y. Kaliwal, M.L. Powis, G. Liu, J.M. Peppercorn, P. Bedard, M.K. Krzyzanowska
Journal: Annals of Oncology (2021)
1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19
Authors: M. Patel, E. Felip, R. Sharkey, M. Krengli, J.D. Chester, A. Sita-Lumsden, U. Mukherjee, B. Russell, A. Loizidou, J. Colomba, C. Andrea Cruz, A. Cabirta, I. Ruiz Camps, J. Brunet, A. Sureda, A. Patriarca, C. Tondini, D.J. Pinato, A. Cortellini
Journal: Annals of Oncology (2021)
1039MO CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Authors: H.A. Tawbi, P.A. Forsyth, F.S. Hodi, A. Algazi, O. Hamid, C.D. Lao, S.J. Moschos, M.B. Atkins, K. Lewis, M.A. Postow, R.P. Thomas, N.I. Khushalani, A.C. Pavlick, M.S. Ernstoff, D.A. Reardon, C. Chung, C-W. Lee, T. Bas, M. Askelson, K.A. Margolin
Journal: Annals of Oncology (2021)
1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
Authors: G. Saito, Y. Kogure, A. Kada, H. Hashimoto, S. Atagi, Y. Takiguchi, H. Saka, N. Ebi, A. Inoue, T. Kurata, T. Yamanaka, M. Ando, T. Shibayama, H. Itani, Y. Nishii, Y. Fujita, N. Yamamoto, A. Gemma
Journal: Annals of Oncology (2021)
<scp>SH2</scp> Domain–Containing Phosphatase 2 Inhibition Attenuates Osteoarthritis by Maintaining Homeostasis of Cartilage Metabolism via the Docking Protein 1/Uridine Phosphorylase 1/Uridine Cascade
Authors: Qianqian Liu, Linhui Zhai, Mingrui Han, Dongquan Shi, Ziying Sun, Shuang Peng, Meijing Wang, Chenyang Zhang, Jian Gao, Wenjin Yan, Qing Jiang, Dijun Chen, Qiang Xu, Minjia Tan, Yang Sun
Journal: Arthritis & Rheumatology (2021)

Protein tyrosine kinases regulate osteoarthritis (OA) progression by activating a series of signal transduction pathways. However, the roles of protein tyrosine phosphatases (PTPs) in OA remain obscure. This study was undertaken to identify specific PTPs involved in OA and investigate their underlying mechanisms.The expression of 107 PTP genes in human OA cartilage was analyzed based on a single-cell sequencing data set. The enzyme activity of the PTP SH2 domain-containing phosphatase 2 (SHP-2) was detected in primary chondrocytes after interleukin-1β (IL-1β) treatment and in human OA cartilage. Mice subjected to destabilization of the medial meniscus (DMM) and IL-1β-stimulated mouse primary chondrocytes were treated with an SHP-2 inhibitor or celecoxib (a drug used for the clinical treatment of OA). The function of SHP-2 in OA pathogenesis was further verified in Aggrecan-CreERT ;SHP2flox/flox mice. The downstream protein expression profile and dephosphorylated substrate of SHP-2 were examined by tandem mass tag labeling-based global proteomic analysis and stable isotope labeling with amino acids in cell culture-labeled tyrosine phosphoproteomic analysis, respectively.SHP-2 enzyme activity significantly increased in human OA samples with serious articular cartilage injury and in IL-1β-stimulated mouse chondrocytes. Pharmacologic inhibition or genetic deletion of SHP-2 ameliorated OA progression. SHP-2 inhibitors dramatically reduced the expression of cartilage degradation-related genes and simultaneously promoted the expression of cartilage synthesis-related genes. Mechanistically, SHP-2 inhibition suppressed the dephosphorylation of docking protein 1 and subsequently reduced the expression of uridine phosphorylase 1 and increased the uridine level, thereby contributing to the homeostasis of cartilage metabolism.SHP-2 is a novel accelerator of the imbalance in cartilage homeostasis. Specific inhibition of SHP-2 may ameliorate OA by maintaining the anabolic-catabolic balance.
Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience
Authors: Ilker Turan, Murat Aladag, Murat Harputluoglu, Sezai Yilmaz, Genco Gencdal, Kamil Yalçin Polat, Figen Özçay, Mesut Akarsu, Tarkan Unek, Zeki Karasu, Murat Zeytunlu, Hale Gokcan Sumer, Erdal Birol Bostanci, Aysun Caliskan Kartal, Deniz Balci, Murat Dayangac, Dinc Dincer, Haydar Adanir, Hakan Dursun, Murat Taner Gulsen, Feyza Gunduz, Hatice Yasemin Balaban, Gökhan Kabaçam, Murat Akyildiz, Fulya Günsar, Ulus Akarca, Ahmet Gurakar, Ramazan Idilman
Journal: Journal of Hepatology (2020)
1592P Willingness to vaccinate and side effects of COVID-19 vaccination in patients with breast cancer and gynecological malignancies
Authors: M. Forster, R. Würstlein, A. König, S. Beyer, T. Degenhardt, A. Burges, F. Trillsch, S. Mahner, N. Harbeck, A. Chelariu-Raicu
Journal: Annals of Oncology (2021)
1153P Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas
Authors: X. Zhang, C. Sun, L. Wang, Y. Miao, L. Wang, X. Fan, P. Yang, Y. Xu, X. Ren, X. Wu, S. Xu
Journal: Annals of Oncology (2021)
1215P EGFR-mutated squamous cell lung cancer and its association with outcomes
Authors: Y. Xia, R. Jin, L. Peng, J. Shou, J. Wang, Y. Jin, F. Liang, J. Zhao, M. Wu, Q. Li, B. Zhang, X. Wu, F. Lan, L. Xia, J. Yan, Y. Shao, J. Stebbing, H. Shen, W. Li
Journal: Annals of Oncology (2021)
1134P Personalized medicine in advanced breast cancer: AI-driven genomic test for CDK4/6 treatment response prediction
Authors: P. Zawadzki, A. Woźna, P. Sztromwasser, W. Majer-Burman, R. Stępień, K. Pacewicz, D. Sielski, M. Gniot, M. Wojtaszewska, M. Dąbrowski, M. Piernik
Journal: Annals of Oncology (2021)
347MO 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial
Authors: N. Sanai, A-C. Tien, A. Tovmasyan, Y-W. Chang, T. Margaryan, K. Hendrickson, J. Eschbacher, W. Yoo, J. Harmon, C. Quarles, L. Alhilali, I. Barani, S.N. Mehta, Z. Mirzadeh
Journal: Annals of Oncology (2021)
ショック状態のため,搬送途中の病院にてPCPS装着,救命し得た血栓弁の1例
Authors: 久米悠太, 石戸谷浩, 堀隆樹, 長嶋光樹, 平谷勝彦, 黒部裕嗣, 米沢数馬, 一色真吾, 佐藤晴瑞
Journal: Circulation (2007)
춘계학술대회 : 포스터발표 ; 간문맥 혈전을 동반한 거대 간암 환자에서 간동맥 항암화학주입요법의 치료 효과: 치료-대조군 연구
Authors: 오현종, 배시현, 김민수, 이소연, 장정원, 김창욱, 장우임, 남순우, 최종영, 윤승규, 이영석, 정규원, 선희식
Journal: Clinical and Molecular Hepatology (2005)

배경/목적: 거대 종괴를 형성하고 문맥 혈전증을 동반한 진행성 간암의 치료로 간동맥에 도관을 유치시킨 후 항암제를 투여하는 간동맥 화학요법이 생존기간 연장에 효과가 있다는 보고와 오히려 간부전을 유발하여 생존 기간을 연장시키지 못한다는 상반된 보고가 있었다. 이에 연자들은 간동맥 화학요법이 이러한 환자들의 생존기간에 미치는 효과 및 그에 관여하는 인자들을 알아보고자 치료-대조군 연구를 시행하였다. 대상 및 방법: 2002년 3월부터 2004년 2월까지
Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma
Authors: Odile Berthier-Vergnes, Laetitia Barbollat-Boutrand, Roxane M. Pommier, Arnaud de la Fouchardière, Patrick Combemale, Maxime Grimont, Noémie Lopez-Ramirez, Julie Caramel, Stéphane Dalle, Jean-Luc Perrot, Caroline Gaudy-Marqueste, Nicolas Macagno, Sandrine Mansard, Fanny Bouquet, Ingrid Masse
Journal: Molecular Cancer (2021)
884P Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Authors: S. Flach, K. Howarth, S. Hackinger, C. Pipinikas, K. McLay, G. Marsico, C. Walz, C.A. Reichel, O. Gires, M. Canis, P. Baumeister
Journal: Annals of Oncology (2021)
Strategies to Turn Real-world Data Into Real-world Knowledge
Authors: Julian C. Hong
Journal: JAMA Network Open (2021)

Samantha Wilkinson, PhD; Alind Gupta, PhD; Nicolas Scheuer, PhD; Eric Mackay, MA, MSc; Paul Arora, PhD; Kristian Thorlund, PhD; Radek Wasiak, PhD; Joshua Ray, MSc; Sreeram Ramagopalan, PhD; Vivek Subbiah, MD
Implications of armed conflict for maternal and child health: A regression analysis of data from 181 countries for 2000–2019
Authors: Mohammed Jawad, Thomas Hone, Eszter P. Vamos, Valeria Cetorelli, Christopher Millett
Journal: PLoS Medicine (2021)

Background Armed conflicts have major indirect health impacts in addition to the direct harms from violence. They create enduring political instability, destabilise health systems, and foster negative socioeconomic and environmental conditions—all of which constrain efforts to reduce maternal and child mortality. The detrimental impacts of conflict on global maternal and child health are not robustly quantified. This study assesses the association between conflict and maternal and child health globally. Methods and findings Data for 181 countries (2000–2019) from the Uppsala Conflict Data Program and World Bank were analysed using panel regression models. Primary outcomes were maternal, under-5, infant, and neonatal mortality rates. Secondary outcomes were delivery by a skilled birth attendant and diphtheria, pertussis, and tetanus (DPT) and measles vaccination coverage. Models were adjusted for 10 confounders, country and year fixed effects, and conflict lagged by 1 year. Further lagged associations up to 10 years post-conflict were tested. The number of excess deaths due to conflict was estimated. Out of 3,718 country–year observations, 522 (14.0%) had minor conflicts and 148 (4.0%) had wars. In adjusted models, conflicts classified as wars were associated with an increase in maternal mortality of 36.9 maternal deaths per 100,000 live births (95% CI 1.9–72.0; 0.3 million excess deaths [95% CI 0.2 million–0.4 million] over the study period), an increase in infant mortality of 2.8 per 1,000 live births (95% CI 0.1–5.5; 2.0 million excess deaths [95% CI 1.6 million–2.5 million]), a decrease in DPT vaccination coverage of 4.9% (95% CI 1.5%–8.3%), and a decrease in measles vaccination coverage of 7.3% (95% CI 2.7%–11.8%). The long-term impacts of war were demonstrated by associated increases in maternal mortality observed for up to 7 years, in under-5 mortality for 3–5 years, in infant mortality for up to 8 years, in DPT vaccination coverage for up to 3 years, and in measles vaccination coverage for up to 2 years. No evidence of association between armed conflict and neonatal mortality or delivery by a skilled birth attendant was found. Study limitations include the ecological study design, which may mask sub-national variation in conflict intensity, and the quality of the underlying data. Conclusions Our analysis indicates that armed conflict is associated with substantial and persistent excess maternal and child deaths globally, and with reductions in key measures that indicate reduced availability of organised healthcare. These findings highlight the importance of protecting women and children from the indirect harms of conflict, including those relating to health system deterioration and worsening socioeconomic conditions.